The Fas/Fas ligand system and cancer

被引:53
作者
Abrahams, VM [1 ]
Kamsteeg, M [1 ]
Mor, G [1 ]
机构
[1] Yale Univ, Sch Med, Dept Obstet & Gynecol, New Haven, CT 06520 USA
关键词
FasL; ovarian cancer; secreted FasL; apoptosis;
D O I
10.1385/MB:25:1:19
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Fas/FasL system has been suggested to play an important role in the establishment of immune privilege status for tumors. by inducing Fas-mediated apoptosis in tumor-specific lymphocytes. However, the role of cell-surface expressed FasL in tumor cell protection has recently become controversial. Our laboratory has focused on the study of the role of the Fas/FasL system in the normal tissue remodeling of the female reproductive tract and in immune-privileged organs. Our studies have demonstrated a connection between sex hormones and the regulation of the Fas/FasL pathway in immune and reproductive cells. More recently, we have investigated the resistance of tumor cells to Fas-mediated apoptosis. We have also characterized a new form of FasL, different from the classical membranal form, which is secreted by ovarian cancer cells. In this review we describe the main techniques used in these studies.
引用
收藏
页码:19 / 30
页数:12
相关论文
共 41 条
[1]  
ABRAHAMS V, 2003, IN PRESS CANC RES
[2]   Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts [J].
Allison, J ;
Georgiou, HM ;
Strasser, A ;
Vaux, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3943-3947
[3]   Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles [J].
Andreola, G ;
Rivoltini, L ;
Castelli, C ;
Huber, V ;
Perego, P ;
Deho, P ;
Squarcina, P ;
Accornero, P ;
Lozupone, F ;
Lugini, L ;
Stringaro, A ;
Molinari, A ;
Arancia, G ;
Gentile, M ;
Parmiani, G ;
Fais, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (10) :1303-1316
[4]  
Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO
[5]  
2-S
[6]   A ROLE FOR CD95 LIGAND IN PREVENTING GRAFT-REJECTION [J].
BELLGRAU, D ;
GOLD, D ;
SELAWRY, H ;
MOORE, J ;
FRANZUSOFF, A ;
DUKE, RC .
NATURE, 1995, 377 (6550) :630-632
[7]  
Ben-Hur H, 2000, EUR J GYNAECOL ONCOL, V21, P53
[8]   CELL-AUTONOMOUS FAS (CD95) FAS-LIGAND INTERACTION MEDIATES ACTIVATION-INDUCED APOPTOSIS IN T-CELL HYBRIDOMAS [J].
BRUNNER, T ;
MOGIL, RJ ;
LAFACE, D ;
YOO, NJ ;
MAHBOUBI, A ;
ECHEVERRI, F ;
MARTIN, SJ ;
FORCE, WR ;
LYNCH, DH ;
WARE, CF ;
GREEN, DR .
NATURE, 1995, 373 (6513) :441-444
[9]   T cell-tumor cell: a fatal interaction? [J].
Chappell, DB ;
Restifo, NP .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 47 (02) :65-71
[10]  
Chappell DB, 1999, CANCER RES, V59, P59